Anti-CD74 immunoconjugates and methods

Details Anti-CD74 immunoconjugates and methods Anti-CD74 immunoconjugates and methods

2003-11-12

2010-11-09

Canella, Karen A (Department: 1643)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Molecular bilayer structure

C424S178100, C424S179100, C424S180100, C424S182100, C424S450000

Reexamination Certificate

active

07829064

ABSTRACT:
Disclosed are compositions that include anti-CD74 immunoconjugates and a therapeutic and/or diagnostic agent. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates compositions in therapeutic and/or diagnostic methods.

REFERENCES:
patent: 4036945 (1977-07-01), Haber
patent: 4046722 (1977-09-01), Rowland
patent: 4331647 (1982-05-01), Goldenberg
patent: 4699784 (1987-10-01), Shih et al.
patent: 4704692 (1987-11-01), Ladner
patent: 4824659 (1989-04-01), Hawthorne
patent: 4916213 (1990-04-01), Scannon et al.
patent: 4918163 (1990-04-01), Young et al.
patent: 4925922 (1990-05-01), Byers et al.
patent: 4932412 (1990-06-01), Goldenberg
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5057313 (1991-10-01), Shih et al.
patent: 5134075 (1992-07-01), Hellstrom et al.
patent: 5171665 (1992-12-01), Hellstrom et al.
patent: 5196337 (1993-03-01), Ochi et al.
patent: 5204095 (1993-04-01), Goodall et al.
patent: 5229275 (1993-07-01), Goroff
patent: 5443953 (1995-08-01), Hansen et al.
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5525338 (1996-06-01), Goldenberg
patent: 5565215 (1996-10-01), Gref et al.
patent: 5567610 (1996-10-01), Borrebaeck et al.
patent: 5593676 (1997-01-01), Bhat et al.
patent: 5620708 (1997-04-01), Amkraut et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5702727 (1997-12-01), Amkraut et al.
patent: 5716595 (1998-02-01), Goldenberg
patent: 5736119 (1998-04-01), Goldenberg et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5789554 (1998-08-01), Leung et al.
patent: 5792845 (1998-08-01), O'Reilly et al.
patent: 5795967 (1998-08-01), Aggarwal et al.
patent: 5798554 (1998-08-01), Grimaldi et al.
patent: 5874540 (1999-02-01), Hansen et al.
patent: 5922302 (1999-07-01), Goldenberg et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6077499 (2000-06-01), Griffiths et al.
patent: 6096289 (2000-08-01), Goldenberg
patent: 6165440 (2000-12-01), Esenaliev
patent: 6183744 (2001-02-01), Goldenberg
patent: 6187287 (2001-02-01), Leung et al.
patent: 6254868 (2001-07-01), Leung et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6331175 (2001-12-01), Goldenberg
patent: 6379698 (2002-04-01), Leamon
patent: 6387350 (2002-05-01), Goldenberg
patent: 6395276 (2002-05-01), Rybak et al.
patent: 6530944 (2003-03-01), West et al.
patent: 6562318 (2003-05-01), Filler
patent: 7074403 (2006-07-01), Goldenberg et al.
patent: 7387779 (2008-06-01), Kalluri
patent: 2002/0071807 (2002-06-01), Goldenberg
patent: 2003/0082154 (2003-05-01), Leamon
patent: 2003/0124058 (2003-07-01), Goldenberg
patent: 2004/0076683 (2004-04-01), Hoarau et al.
patent: 0 332 865 (1989-09-01), None
patent: 0 510 949 (1992-10-01), None
patent: WO 91/13974 (1991-09-01), None
patent: WO 94/27638 (1994-12-01), None
patent: WO 95/09917 (1995-04-01), None
patent: WO 96/04925 (1996-02-01), None
patent: WO 98/42378 (1998-10-01), None
patent: WO 98/50435 (1998-11-01), None
patent: WO 99/02567 (1999-01-01), None
patent: WO 99/54440 (1999-10-01), None
patent: WO 00/29584 (2000-05-01), None
patent: WO 00/67795 (2000-11-01), None
patent: WO 00/74718 (2000-12-01), None
US 6,558,648, 05/2003, Griffiths et al. (withdrawn)
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979).
Breen et al, Clinical Immunology, 2003, vol. 109, pp. 119-129.
Nagel et al, Leukemia, 2005, vol. 19, pp. 841-846.
Schlom (In: Molecular Foundations of Oncology, Sameule Broader, Ed, 1991, pp. 95-134).
Greenwood et al, ‘Effector functions of atched sets of recombinant human IgG subclass antibodies’, In: Protein engineering of antibody molecules, for therapetuic and Prophylatic Applications in Man, Clark, Ed., 1993, pp. 89 and 97).
Nakagawa et al, (Journal of Neurooncology, 1999, vol. 45, pp. 175-183.
Goto et al (Blood, 1994, vol. 84, pp. 1922-1930).
Hannsen et al (Biochemical Journal, 1996, vol. 320, pp. 293-300).
Kratz et al (Crit Rev Drug Carrier Sys, 1999, vol. 16, pp. 245-288).
Torchilin et al (Crit Rev Ther Drug Carriers, 1991, vol. 7, pp. 275-308).
Bagshawe et al (Curr Opin Immunol, 1999, vol. 11, pp. 579-583).
Hua et al (Human Pathology, 1998, vol. 29, pp. 1441-1446).
Hong et al (Journal of Pharmacy and Pharmacology, Jan. 2002, vol. 54, pp. 51-58).
Ansel et al.,Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th Ed., Lea & Feibiger (1990).
Bally, et al.,J. Liposome Res., 8(3):299 (1998).
Bendas,Biodrugs, 15(4):215 (2001).
Bendig et al.,Methods: A Companion to Methods in Enzymology, 8:83 (1995).
Bird et al.,TIBTECH, 9:132 (1991).
Bom et al.,J. Controlled Release, 74:325 (2001).
Carter et al.,Proc. Natl. Acad Sci. USA, 89:4285 (1992).
Cochlovius et al.,Cancer Research, 60: 4336 (2000).
Coligan et al (eds.),Current Protocols in Immunology, vol. 1, pp. 2.5.1-2.6.7; pp. 2.7.1-2.7.12; 2.8.1-2.8.10; 2.9.1-2.9.3, and 2.10-2.10.4, John Wiley & Sons (1991).
Coloma et al.,Nature Biotech, 15:159 (1997).
Constantinides et al.,Pharm. Res., 17(2):175 (2000).
Courtenay-Luck, “Genetic Manipulation of Monoclonal Antibodies”,Monoclonal Antibodies: Production, Engineering, and Clinical Application, pp. 166-179, Ritter et al., eds., Cambridge University Press (1995).
Edelman et al,Methods in Enzymology, vol. 1, p. 422, Academic Press (1955).
FitzGerald et al.,Protein Eng., 10(10):1221 (1997).
Flavell et al.,Cancer Res., 57:4824 (1997).
Freedman et al, “Non-Hodgkin's Lymphomas,” inCancer Medicine, vol. 2, 3rd Edition, pp. 2028-2068, Holland et al (eds.), Lea & Febiger (1993).
French et al.,Leukemia Res., 20(7):607 (Jul. 1996).
Gennaro,Remington's Pharmaceutical Sciences, 18th Ed., Mack Publishing Co. (1990).
Gennaro,Remington's Pharmaceutical Sciences, 19th Ed., vol. I and II, Mack Publishing Co. (1995).
Ghetie et al.,Cancer Res., 48:2610 (1988).
Goldenberg,Scientific American, Science&Medicine, 1:64 (1994).
Goldenberg,Semin. Nucl. Med., 19(4):332 (1989).
Goldenberg,CA-A Cancer J. for Clinicians, 44(1):43 (1994).
Goodman and Gilman's The Pharmacological Basis of Therapeutics, 7th Ed., MacMillan Publishing Co. (1985).
Green et al,Nature Genet., 7:13 (1994).
Hansen et al.,Biochem. J., 320:293 (1996).
Harlow & Lane (eds),Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1988).
Hasan et al.,Prog. Clin. Biol. Res., 288:471 (1989).
Hekman et al.,Cancer Immunol. Immunother., 32:364 (1991).
Hess et al.,Blood, 89(6): 2203 (1997).
Huse et al.,Science, 246:1275 (1989).
Johnson et al.,Current Opin. Struct. Biol., 3:564 (1993).
Jones et al.,Nature, 321:522 (1986).
Jori et al.,Photodynamic Therapy of Tumors and Other Diseases, Libreria Progetto (1985).
Juweid et al,Nuc. Med. Comm., 18:142 (1997).
Juweid et al.,Cancer Res. (suppl.), 55:5899s (1995).
Kaminski et al.,New Eng. J. of Med., 329(7):459 (1993).
Kiesel et al.,Leukemia Res., 11(12):1119 (1987).
Kirpotin, et al,Biochemistry, 36:66 (1997).
Köhler et al.,Nature, 256:495 (1975).
Koning et al.,Biochim. Biophys. Acta, 1420:153 (1999).
Kreitman et al.,Cancer Research, 53:819 (1993).
Larrick et al.,Methods: A Companion to Methods in Enzymology, 2(2):106 (1991).
Leonard et al.,Blood, 94(10), supp. 1, part 1, abstract #404 (1999).
Leung et al,Hybridoma, 13:469 (1994).
Leung et al.,J. Immunol., 154:5919 (1995).
Leung et al.,Mol. Immunol., 32(17/18):1413 (1995).
Levine et al.,Neurology, 52(8):1701 (1999).
Li et al.,Cellular Immunol., 118:85 (1989).
Lonberg et al.,Nature, 368:856 (1994).
Longo,Curr. Opin. Oncol., 8:353 (1996).
Lopes de Menezes et al.,Cancer Res., 58:3320 (1998).
Lopes de Menezes, et al.,J. Liposome Res., 9(2):199 (1999).
Lundberg,J. Pharm. Sci., 83(1):72 (1994).
Lundberg,Int. J. Pharm., 109:73 (1994).
Lundberg et al.,Int. J. Pharm., 134:119 (1996).
Lundberg,J. Pharm. Pharmacol., 49:16 (1997).
Lundberg,Anti-Cancer Drug Design, 13:453 (1998).
Lundberg et al.,J. Pharm. Pharmacol., 51:1099 (1999).
Lundberg et al,Int. J. Pharm., 205:101 (2000).
Mack et al.,Proc. Natl. Acad. Sci. USA, 92:7021 (1995).

Affiliated with

Also associated with

Rating

Anti-CD74 immunoconjugates and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-CD74 immunoconjugates and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-CD74 immunoconjugates and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4243909